Truist Financial Corp Sells 6,645 Shares of Humana Inc. (NYSE:HUM)

Share on StockTwits

Truist Financial Corp lowered its holdings in Humana Inc. (NYSE:HUM) by 32.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,796 shares of the insurance provider’s stock after selling 6,645 shares during the period. Truist Financial Corp’s holdings in Humana were worth $5,660,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of HUM. Catalyst Private Wealth LLC purchased a new position in Humana in the third quarter worth $25,000. Graves Light Private Wealth Management Inc. purchased a new position in Humana in the fourth quarter worth $27,000. SRS Capital Advisors Inc. boosted its position in Humana by 322.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 76 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 58 shares during the last quarter. First Horizon Advisors Inc. purchased a new position in Humana in the fourth quarter worth $31,000. Finally, Exchange Traded Concepts LLC boosted its position in Humana by 74.5% in the fourth quarter. Exchange Traded Concepts LLC now owns 82 shares of the insurance provider’s stock worth $34,000 after purchasing an additional 35 shares during the last quarter. 91.90% of the stock is currently owned by institutional investors and hedge funds.

Shares of HUM opened at $411.73 on Thursday. The stock’s 50-day simple moving average is $399.82 and its 200 day simple moving average is $407.21. The stock has a market capitalization of $53.12 billion, a price-to-earnings ratio of 13.20, a price-to-earnings-growth ratio of 1.57 and a beta of 0.86. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.81 and a current ratio of 1.81. Humana Inc. has a 52-week low of $319.33 and a 52-week high of $474.70.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 3rd. The insurance provider reported ($2.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.05. The business had revenue of $19.06 billion for the quarter, compared to analysts’ expectations of $18.76 billion. Humana had a return on equity of 22.74% and a net margin of 5.58%. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.28 EPS. On average, research analysts forecast that Humana Inc. will post 18.66 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 30th. Shareholders of record on Wednesday, March 31st will be paid a $0.70 dividend. This is a positive change from Humana’s previous quarterly dividend of $0.63. This represents a $2.80 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend is Tuesday, March 30th. Humana’s dividend payout ratio is currently 15.67%.

Several research analysts have weighed in on the company. Argus boosted their price objective on Humana from $430.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, January 6th. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating and set a $447.00 price target on the stock. in a research report on Tuesday, March 30th. Finally, Royal Bank of Canada raised Humana from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $429.00 to $479.00 in a research report on Monday, January 4th. One research analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $461.38.

In other Humana news, Director Jorge S. Mesquita bought 375 shares of the firm’s stock in a transaction on Monday, March 8th. The shares were acquired at an average cost of $403.37 per share, for a total transaction of $151,263.75. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Timothy S. Huval sold 3,696 shares of the company’s stock in a transaction dated Monday, February 22nd. The stock was sold at an average price of $377.96, for a total value of $1,396,940.16. Following the completion of the transaction, the insider now owns 13,068 shares in the company, valued at $4,939,181.28. The disclosure for this sale can be found here. 0.42% of the stock is owned by corporate insiders.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Debt-To-Equity Ratio

Want to see what other hedge funds are holding HUM? Visit to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.